AI Science Tracker

Absci

1 discovery from 2023

Discoveries

Absci

Zero-shot generative models design HER2 antibodies, with 71 low-nanomolar binders among 421 characterised

Source check: Needs source check. Not independent scientific confirmation.

Finding: Shanehsazzadeh et al. (Absci) described generative models for de novo antibody design against HER2 without further optimisation, combined with high-throughput screening of about 10^6 HCDR variants; binding rates were 10.6 percent (HCDR3) and 1.8 percent (HCDR123), 71 of 421 characterised binders had low-nanomolar affinity by SPR, 11 were functionally equivalent or better than trastuzumab, and one showed about 3x higher cell-based potency. Preprint, not peer-reviewed at this version; a later journal version should be checked. Abstract-level review.

Technology: Generative deep learning models for antibody design

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
Generative models proposed HCDR variants that were then screened for binding.
Test and result
Designed antibodies were expressed and measured by high-throughput screening and SPR, with comparison to trastuzumab (per abstract).
Limitation / still unknown
Peer review, in vivo activity, the reach beyond one target and the model details were not assessed; one organisation authored and tested the designs.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/PPR/PPR589043

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 17 Nov 2026. Review scope: abstract and bibliographic metadata (Europe PMC); full text not assessed.

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open the interactive profile for the timeline, or browse all organizations and model families.